Table 2.
Distribution of lymph node regions containing cancer in the 154 breast cancer patients
| Total (n = 154) n (%) |
Primary
non-metastatic (n = 55) n (%) |
De-novo metastatic (n = 49) n (%) |
Recurrent
without RNI history (n = 35) n (%) |
Recurrent
with RNI history (n = 15) n (%) |
|
|---|---|---|---|---|---|
| ALN-I | 109 (70.8%) | 54 (98.2%) | 47 (95.9%) | 4 (11.4%) | 4 (26.7%) |
| ALN-II | 46 (29.9%) | 15 (27.3%) | 23 (46.9%) | 8 (22.9%) | 0 (0%) |
| ALN-III | 36 (23.4%) | 10 (18.2%) | 19 (38.8%) | 6 (17.1%) | 1 (6.7%) |
| RN | 17 (11.0%) | 7 (12.7%) | 6 (12.2%) | 3 (8.6%) | 1 (6.7%) |
| SC-M | 68 (44.2%) | 12 (21.8%) | 25 (51.0%) | 21 (60.0%) | 10 (66.7%) |
| SC-L | 36 (23.4%) | 7 (12.7%) | 12 (24.5%) | 15 (42.9%) | 2 (13.3%) |
| IMN | 36 (23.4%) | 10 (18.2%) | 7 (14.3%) | 14 (40.0%) | 5 (33.3%) |
ALN-I, axillary lymph node level I; ALN-II, axillary lymph node level II; ALN-III, axillary lymph node level III; FDG, 18-fludeoxyglucose; IMN, internal mammary nodes; RN, Rotter’s nodes; RNI, regional node irradiation; SC-L, lateral supraclavicular; SC-M, medial supraclavicular.